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Abstract
Major depressive disorder (MDD) is the most prevalent comorbid mental disorder among
people with substance use disorders. The MDD can be both primary and substance-induced
and its accurate diagnosis represents a challenge for clinical practice and treatment
response. Recent studies reported alterations in the circulating expression of inflammatory
mediators in patients with psychiatric disorders, including those related to substance use.
The aim of the study was to explore TNF-α, IL-1β, CXCL12, CCL2, CCL11 (eotaxin-1) and
CX3CL1 (fractalkine) as potential biomarkers to identify comorbid MDD and to distinguish
primary MDD from substance-induced MDD in patients with substance disorders. Patients
diagnosed with cocaine (CUD, n = 64) or alcohol (AUD, n = 65) use disorders with/without
MDD were recruited from outpatient treatment programs [CUD/non-MDD (n = 31); CUD/pri-
mary MDD (n = 18); CUD/cocaine-induced MDD (N = 15); AUD/non-MDD (n = 27); AUD/pri-
mary MDD (n = 16) and AUD/alcohol-induced MDD (n = 22)]. Sixty-two healthy subjects
were also recruited as control group. Substance and mental disorders were assessed
according to “Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revi-
sion” (DSM-IV-TR) and a blood sample was collected for determinations in the plasma. The
cocaine group showed lower TNF-α (p<0.05) and CCL11 (p<0.05), and higher IL-1β
(p<0.01) concentrations than the control group. In contrast, the alcohol group showed higher
IL-1β (p<0.01) and lower CXCL12 (p<0.01) concentrations than the control group. Regard-
ing MDD, we only observed alterations in the cocaine group. Thus, CUD/MDD patients
showed lower IL-1β (p<0.05), CXCL12 (p<0.05) and CCL11 (p<0.05), and higher CXC3CL1







Citation: Garcı́a-Marchena N, Barrera M, Mestre-
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(p<0.05) concentrations than CUD/non-MDD patients. Moreover, while CUD/primary MDD
patients showed higher CCL11 (p<0.01) concentrations than both CUD/non-MDD and
CUD/cocaine-induced MDD patients, CUD/cocaine-induced MDD patients showed lower
CXCL12 (p<0.05) concentrations than CUD/non-MDD patients. Finally, a logistic regression
model in the cocaine group identified CXCL12, CCL11 and sex to distinguish primary MDD
from cocaine-induced MDD providing a high discriminatory power. The present data sug-
gest an association between changes in inflammatory mediators and the diagnosis of pri-
mary and substance-induced MDD, namely in CUD patients.
Introduction
Major depressive disorder (MDD) is the most prevalent comorbid mental condition in sub-
jects with substance use disorders (SUD) and closely related to their poor prognosis. As
expected, due to their marked clinical severity, these dual diagnosed patients also present con-
siderable psychosocial acuteness and make greater use of health resources, including emer-
gency services and psychiatric admissions [1–3]. The identification of MDD in substance
users, however, is often complicated because of its inherent characteristics, that is to say, the
acute and chronic effects related to substance consumption/withdrawal can mimic depression.
Currently, diagnosis is syndromic and established with clinical criteria using “Diagnostic and
Statistical Manual of Mental Disorders 4th Edition Text Revision” (DSM-IV-TR), “DSM 5th
Edition” (DSM-5) [4–5] or “International Classification of Diseases and Related Health Prob-
lems 10th Edition” (ICD-10) [6], the availability of specific biomarkers to facilitate the diagno-
sis of MDD in SUD are therefore required [7]. Among others, modulation of inflammatory
mediators such as cytokines and chemokines has been recognized as a possible target. A grow-
ing body of literature has established that cytokines can play a critical role in the pathogenesis
of both MDD [8–9] and SUD [10–13]. Preclinical and clinical studies in MDD and SUD have
reported alterations in the immune system and dysregulation of the hypothalamic-pituitary-
adrenal axis (HPA) [14–15]. These changes result in a chronic inflammatory response and a
disruption of brain integrity and homeostasis as consequence of neuroinflammation [16]. In
the brain, glial activation results in the release of cytokines such as tumor necrosis factor-alpha
(TNF-α) and interleukin-1 beta (IL-1β), inflammatory mediators that influence the central
immune system, modulate neural activity, and regulate the HPA axis [14, 17–18]. Chemokines,
small chemoattractant proteins, also act as modulators in neuronal transmission and partici-
pate in the communication between glia and neurons [8, 19].
An increasing quantity of research has focused on the leading role of inflammatory media-
tors in the pathophysiology of a variety of psychiatric problems including bipolar [20] and
post-traumatic stress disorders [21], schizophrenia [22], and MDD [23]. With respect to
MDD, patients show increased serum levels of TNF-α and it has been reported that elevated
serum levels of CCL11 are associated with suicidal ideations in such patients [24]. Moreover,
there are studies suggesting that inflammatory markers have the potential to predict antide-
pressant treatment outcomes [25–26]. Regarding SUD, preclinical models of cocaine exposure
have described that stromal derived factor-1/SDF-1 (CXCL12) participates in the modulation
of cocaine-induced behavioral effects such as locomotion and stereotypes [27]. Previous stud-
ies in abstinent subjects with CUD found a positive correlation between plasma levels of IL-1β,
fractalkine (CX3CL1), and CXCL12 with a number of DSM-IV-TR criteria for CUD, and with
increased prevalence of comorbid psychiatric disorders relative to those users with no other
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psychiatric diagnosis [11]. With respect to alcohol, in preclinical models it has been reported
to disrupt the cytokine profile during neuronal differentiation and influence adult neurogen-
esis, thus providing potential mechanisms to understand alcohol effects on cerebral develop-
ment [28]. Other clinical studies have indicated that alcohol dependence is characterized by
enhanced glial IL-1β in the cerebral cortex [29] and elevated chemokine monocyte chemotac-
tic protein 1/MCP-1 (CCL2) in different brain regions [10]. Furthermore, a recent study in
patients diagnosed with alcohol use disorders (AUD) showed lower plasma levels of CXCL12
and CX3CL1 than in controls. Additionally, AUD patients with comorbid depressive and/or
anxiety disorders have been reported to have alterations in the plasma levels of the chemokine
eotaxin-1 (CCL11) [30].
Because the peripheral alterations of inflammatory molecules may modulate and/or reflect
neuroinflammatory events in the brain, certain cytokines and chemokines could be reliable
candidates to detect MDD in SUD patients. Changes in peripheral inflammatory mediators
might thus contribute to improving diagnosis, treatment strategy, and medical approach for
these psychiatric patients [7, 31]. The aim of the present study is to explore whether relevant
proinflammatory cytokines such as TNF-α, and IL-1β, and chemokines such as CXCL12,
CCL2, CCL11, and CX3CL1 could be potential biomarkers for the detection of co-occurrence




The present cross-sectional study was conducted in white Caucasian population, and included
SUD [cocaine (CUD) or alcohol (AUD)] patients diagnosed with/without comorbid MDD,
and healthy control subjects. Patients were recruited at the addiction treatment facilities of the
Instituto de Neuropsiquiatría y Adicciones-Parc Salut Mar (Barcelona, Spain),Hospital Univer-
sitario 12 de Octubre (Madrid, Spain), and Centro Provincial de Drogodependencias (Málaga,
Spain). Control participants were included from data bases of healthy subjects willing to par-
ticipate in medical research projects at the Unidad de Farmacología del IMIM-Hospital del
Mar Research Institute (Barcelona, Spain),Hospital Universitario 12 de Octubre (Madrid,
Spain), andHospital Regional Universitario de Málaga (Málaga, Spain).
Cocaine (n = 64) and alcohol (n = 65) groups were classified into six different subgroups:
CUD with no MDD (CUD/non-MDD, n = 31), CUD with primary MDD (CUD/primary
MDD, n = 18); CUD with cocaine-induced MDD (CUD/cocaine-induced MDD, n = 15),
AUD with no MDD (AUD/non-MDD, n = 27), AUD with primary MDD (AUD/primary
MDD, n = 16); AUD with alcohol-induced MDD (AUD/alcohol-induced MDD, n = 22).
All the subjects met the inclusion criteria, which were: both genders, age� 18 years old up
to 65 years of age and at least 4 weeks of abstinence in the case of subjects with SUD. Those
patients who were diagnosed with MDD had to be in remission and “Hamilton Depression
Rating Scale” (HDRS) scores had to be lower than 6. We considered 4 weeks of abstinence
(SUD) and remission phase (MDD) because patients have to be as pathophysiologically stable
as possible for clinical assessments and biochemical determinations. The exclusion criteria
included: cognitive or language limitations that precluded evaluations and pregnant or breast-
feeding women. SUD patients suffering from any psychiatric disorder in Axis I (DSM-IV-TR)
[4] other than MDD and/or CUD/AUD (except from nicotine use disorder) were excluded. In
the control group, participants with psychiatric disorders in Axis I (DSM-IV-TR), SUD
(except nicotine use disorder) or family history of MDD were also excluded. Other excluding
factors for all participants were: use of anti-inflammatory drugs or MAOI’s, personal history of
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cancer; major surgery within 6 months prior to the study; long-term inflammatory disease;
any chronic illnesses that could interfere in the study such as cardiovascular, respiratory, renal,
hepatic, endocrine, gastro-intestinal, hematological, neurological diseases; and infectious dis-
eases (including HIV, hepatitis B, and hepatitis C). Clinical assessments and blood/urine anal-
yses were performed to assure these participation criteria.
Ethics statements
Written informed consents were obtained from each participant after a complete description
of the study. All the participants had the opportunity to discuss any questions or issues. The
study and protocols for recruitment were approved by the Ethics Committee of theHospital
Regional Universitario de Málaga (CP14/00173, CP14/00212 and PI13/02261) and by the
Research Ethical Committee from the CEIC-Parc de Salut Mar (2012/4903/I; 2012/4751/I;
2009/3494/I) in accordance with the Ethical Principles for Medical Research Involving Human
Subjects adopted in the Declaration of Helsinki by the World Medical Association (64th WMA
General Assembly, Fortaleza, Brazil, October 2013), Recommendation No. R (97) 5 of the
Committee of Ministers to Member States on the Protection of Medical Data (1997), and
Spanish data protection act (Ley Orgánica 15/1999 de Protección de Datos, LOPD). All collected
data were given code numbers in order to maintain privacy and confidentiality.
Clinical assessments
Substance and non-substance use disorders were diagnosed according to the DSM-IV-TR cri-
teria [4] using the Spanish version of the “Psychiatric Research Interview for Substance and
Mental Disorders” (PRISM) [4, 32]. PRISM is a semi-structured interview that has demon-
strated good psychometric properties in terms of test-retest reliability, inter-rater reliability,
and validity for primary MDD and substance-induced MDD, with kappa ranging from 0.66
and 0.75 [32–33]. All the interviews were performed by trained and experienced psychologists.
Collection of plasma samples
Blood samples were obtained in the morning after fasting for 8–12 h by experienced nurses.
Participants were comfortably seated in a chair for 5 min before the blood draw, and were
asked whether they had allergies, phobias or a history of vaso-vagal response during previous
injections or blood draws. The participants could be placed in the supine position by adjusting
the chair (backrest) if necessary. After the blood draw, participants were invited for breakfast
prior to the psychiatric interviews.
Venous blood was extracted into 10 mL K2 EDTA tubes (BD, Franklin Lakes, NJ, USA) and
immediately processed to obtain plasma. Blood samples were centrifuged at 2,200 x g for 15
min (4˚C) and individually assayed to detect infectious diseases by 3 commercial rapid tests
for HIV, hepatitis B, and hepatitis C (Strasbourg, Cedex, France). Finally, plasma samples were
individually characterized, registered, and stored at -80˚C until further analyses.
Multiplex immunoassays
Proinflammatory cytokines and chemokines were chosen based on previous studies regarding
relevant inflammatory mediators in psychiatric disorders and SUD using a Luminex Platform
for quantification [11, 13, 34]. A Bio-Plex Suspension Array System 200 (Bio-Rad Laboratories,
Hercules, CA, USA) was used to quantify cytokine and chemokine concentrations in plasma
with a ProcartaPlex Immunoassay panel and an appropriate Plasma Standard Diluent Kit
(Invitrogen, ThermoFisher Scientific, Waltham, MA, USA). A human cytokine/chemokine
Inflammatory mediators as biomarkers for dual depression
PLOS ONE | https://doi.org/10.1371/journal.pone.0213791 March 14, 2019 4 / 17
6-plex panel was used to simultaneously detect the following analytes: TNF-α, IL-1β, CXCL12;
CCL2, CCL11, and CX3CL1. The measurements of these inflammatory mediators in plasma
were performed following the manufacturer´s instructions [11]. Raw data (mean fluorescence
intensity) were analyzed using the Bio-Plex Manager Software 4.1 (Bio-Rad laboratories, Her-
cules, CA, USA). Plasma concentrations were expressed as pg/mL. According to manufactur-
er’s specifications (ProcartaPlex Human Cytokine/Chemokine Simplex Kit), assay sensitivity
and standard curve range for each analyte were as follows: 0.4 pg/mL and 8.54–35,000 pg/mL
for TNF-α (catalog #: EPX01A-10223-901); 0.2 pg/mL and 2.44–10,000 pg/mL for IL-1β (cata-
log #: EPX01A-10224-901); 20.5 pg/mL and 17.1–70,000 pg/mL for CXCL12 (catalog #:
EPX01A-12138-901); unknown and 37.5–23,300 pg/mL for CCL2 (catalog #: EPX01B-10281-
901); 1.4 pg/mL and 0.61–2,500 pg/mL for CCL11 (catalog #: EPX01B-12120-901); and 0.5 pg/
mL and 2.08–8,500 pg/mL for CX3CL1 (catalog #: EPX01A-12121-901). Inter-assay and intra-
assay (samples in duplicate) coefficients of variation (%CV) were as follows: 7.1% and 6.5% for
TNF-α;<5% and 8.9% for IL-1β; 7.8% and 9.0% for CCL11; 7.2% and 6.4% for CX3CL1; <5%
and 9.8% for CCL2; and 5% and 10.7% for CXCL12.
Statistical analysis
All data in the tables are expressed as number and percentage of subjects [n (%)] or mean and
standard deviation [mean (SD)]. The significance of differences in categorical and normal con-
tinuous variables was determined using Fisher’s exact test (chi-square test) and Student’s t-
test, respectively.
One-way analysis of covariance (ANCOVA) was performed to assess the effects of indepen-
dent factors (i.e., grouping variables such as types of SUD, diagnosis of MDD, and types of
MDD) on the plasma concentrations of cytokines and chemokines (dependent variables), con-
trolling for additional independent variables and covariates [e.g., sex, age, body mass index
(BMI), and antidepressant medication]. The post hoc tests for multiple comparisons were per-
formed using Sidak’s correction test. Prior to performing one-way ANCOVA, logarithm (10)-
transformation for dependent variables was used to ensure statistical assumptions for positive
skewed distributions.
Binary logistic models were employed to distinguish between primary MDD and sub-
stance-induced MDD for SUD patients using full models that included cytokine and chemo-
kine concentrations, sex, age, and BMI, and adjusted models (variables were chosen using a
backward stepwise approach). Receiver operating characteristic (ROC) analysis was performed
to determine the accuracy of these models comparing the area under the curve (AUC) and rep-
resentative cut-off scores for the distinction between types of MDD, which included estima-
tions of sensitivity and specificity.
Statistical analysis was carried out with the GraphPad Prism version 5.04 (GraphPad Soft-
ware, San Diego, CA, USA), and IBM SPSS Statistical version 22 (IBM, Armonk, NY, USA). A
p-value<0.05 was considered statistically significant.
Results
Sociodemographic and clinical characteristics of the sample
Table 1 shows the sociodemographic characteristics and depression-related variables of 191
participants in this cross-sectional study who were divided into 3 groups: cocaine, alcohol and
control groups.
The mean age of the cocaine group was 37.6 years, and 23.4% were women. The most com-
mon marital status was single, mainly in cocaine-induced MDD patients, with elementary edu-
cation (51.6%). As compared with the control group, we observed significant differences in the
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percentage of women (CUD/non-MDD patients were 19% women; p<0.05), marital status
(CUD/primary MDD patients were mainly separated; p<0.01), education (p<0.001), and occu-
pation (CUD/cocaine-induced MDD patients were mainly unemployed; p<0.01). In the alcohol
group, the mean age was 46.9 years, and 33.8% were women. In contrast, cohabiting was the
most common marital status, and education at secondary or higher level reached 69.2%. The
comparison with the control group revealed significant differences in the mean age (p<0.001),
BMI (AUD/primary MDD had higher BMI than controls; p<0.05), and education (p<0.001).
Regarding MDD-related variables in the cocaine group, the mean age of onset was 32.5
years and 3.2 episodes. However, there were significant differences in the age of the last epi-
sode when primary and cocaine-induced patients were compared (p<0.05). In the alcohol
group, the mean age of onset was 40.6 years and 3.81 episodes. No differences were found in
the age of the last episode in AUD patients. Finally, although remission and current treatment
with antidepressants were apparently different as compared both primary and substance-
Table 1. Baseline sociodemographic and clinical characteristics of the study sample.
VARIABLES CONTROL
GROUP (n = 62)












MDD (n = 22)
SOCIODEMOGRAPHIC VARIABLES
Age [Mean (SD)] Years 34.82 (6.23) 36.52 (6.47) 40.89 (10.11) 35.67 (9.34) 46.78 (6.71)
aaa
47.31 (6.03) aaa 46.64 (8.77) aaa
BMI [Mean (SD)] Kg/m2 24.89 (3.49) 24.64 (3.05) 26.69 (5.75) 26.16 (4.23) 25.63 (3.87) 27.68 (4.58) a 25.23 (3.57)
Sex [n (%)] Women 29 (46.8) 6 (19.4) a 5 (27.8) 4 (26.7) 7 (25.9) 5 (31.3) 10 (45.5)
Men 33 (53.2) 25 (80.6) 13 (72.2) 11 (73.3) 20 (74.1) 11 (68.8) 12 (54.5)
Marital Status [n
(%)]
Single 28 (45.2) 12 (38.7) 6 (33.3) aa 11 (73.3) 9 (33.3) 3 (18.8) 8 (36.4)
Cohabiting 24 (38.7) 11 (35.5) 3 (16.7) 1 (6.7) 13 (48.1) 7 (43.8) 9 (40.9)
Separated 6 (9.7) 8 (25.8) 9 (50.0) 3 (20.0) 5 (18.5) 5 (31.3) 4 (18.2)
Widow/er 4 (6.5) - - - - 1 (6.3) 1 (4.5)
Education [n (%)] Elementary 1 (1.6) 16 (51.6) aaa 10 (55.6) aaa 7 (46.7) aaa 10 (37.0) aaa 4 (25.0) aaa 6 (27.3) aaa
Secondary 22 (35.5) 11 (35.5) 4 (22.2) 4 (26.7) 14 (51.9) 8 (50.0) 7 (31.8)
University 39 (62.9) 4 (12.9) 4 (22.2) 4 (26.7) 3 (11.1) 4 (25.0) 9 (40.9)
Occupation [n (%)] Employed 41 (66.1) 15 (48.4) 10 (55.6) 4 (26.7) aa 12 (44.4) 6 (37.5) 9 (40.9)
Unemployed 21 (33.9) 16 (51.6) 8 (44.4) 11 (73.3) 15 (55.6) 10 (62.5) 13 (59.1)
DEPRESSION-RELATED VARIABLES
Age of onset [Mean
(SD)]
Years - - 33.33 (11.30) 31.40 (8.63) - 42.31 (7.67) 39.29 (9.21)
Number of episodes [Mean (SD)] - - 2.44 (1.89) 4.20 (6.47) - 3.54 (5.13) 4.00 (5.66)
Age at last episode
[Mean (SD)]
Years - - 38.61 (10.25) 31.50 (5.17) c - 47.23 (6.07) 46.64 (8.77)
Remission [Mean
(SD)]
Months - - 15.00 (19.88) 29.56 (35.64) - 6.38 (4.05) 14.24 (18.24)
Current antidepressant treatment
[n (%)]
- - 10 (55.6) 4 (26.7) 5 (18.5) 11 (68.8) bb 9 (40.9)
Family history of MDD [n (%)] - 5 (16.1) 9 (50.0) 4 (26.7) 15 (55.6) 9 (56.3) 12 (54.5)
(a) p<0.05
(aa) p<0.01 and
(aaa) p<0.001 denote significant differences versus control group
(bb) p<0.01 denotes significant differences versus non-MDD subgroup
(c) p<0.05 denotes significant differences versus primary MDD subgroup
Abbreviations: AUD = alcohol use disorders; BMI = body mass index; CUD = cocaine use disorders MDD = major depressive disorders
https://doi.org/10.1371/journal.pone.0213791.t001
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induced MDD subgroups in the cocaine and alcohol groups, statistical analysis found no sig-
nificant differences.
Inflammatory mediators in relation to substance use disorders
The impact of SUD on the plasma concentrations of proinflammatory cytokines and chemo-
kines was investigated using a one-way ANCOVA [cocaine group (CUD/non-MDD patients),
alcohol group (AUD/non-MDD patients), and control group], and controlling for sex, age,
and BMI. Plasma concentrations and statistical analysis of inflammatory mediators according
to SUD are described in Table 2.
One-way ANCOVA revealed a main effect of SUD on TNF-α (p<0.05) concentrations.
While the cocaine group showed significantly lower TNF-α concentrations than the control
(p<0.05), there were no differences in TNF-α concentrations between the alcohol group and
the control. In the case of IL-1β, there was also a main effect of SUD (p<0.01) and both cocaine
and alcohol groups reported higher IL-1β concentrations than the control (p<0.01). Regarding
chemokine concentrations, the statistical analysis revealed a main effect of SUD on CXCL12
(p<0.01) and CCL11 (p<0.05) concentrations. The multiple comparisons test showed signifi-
cantly lower CXCL12 concentrations in the alcohol group than in the cocaine (p<0.05) and
control (p<0.01) groups, but also significantly lower CCL11 (p<0.05) in the cocaine group
than in the control (p<0.05). In contrast, no main effects of SUD were detected on plasma
concentrations of CCL2 and CX3CL1.
Inflammatory mediators in relation to comorbid major depressive
disorders
We investigated whether comorbid MDD was associated with alterations in the plasma con-
centrations of these inflammatory mediators in the two groups of SUD patients. A one-way
ANCOVA was performed for the cocaine (CUD/non-MDD and CUD/MDD patients) and
Table 2. Plasma concentrations of inflammatory mediators in participants grouped according to the type of substance use disorder.
VARIABLE CONTROL GROUP
(n = 62)
COCAINE GROUP (CUD) Non-MDD
(n = 31)




Mean ± SD Mean ± SD Mean ± SD
TNF-α (pg/mL) 11.32±4.91 8.00±5.11 a 10.27±5.97 4.540 2,
113
0.013
IL-1β (pg/mL) 0.724±0.76 1.346±0.87 aa 1.764±1.13 aa 7.891 2,103 0.001
CXCL12 (pg/
mL)
287.2±44.53 287.9±60.34 240.1±77.69 aa, b 5.662 2,114 0.005
CCL2 (pg/mL) 35.29±16.37 38.70±9.303 39.01±16.28 2.198 2,
114
0.116





2.606±1.37 1.987±1.67 1.839±1.09 1.886 2,
113
0.156
(1) Statistical analysis was conducted on the logarithmic transformed values to ensure statistical assumptions. Data were analyzed by ANCOVA controlling for age, sex,
and BMI
(a) p<0.05 and
(aa) p<0.01 denote significant differences versus control group after post hoc comparisons
(b) p<0.05 denotes significant differences versus cocaine non-MDD group after post hoc comparisons
Missing participants: TNF-α (n = 1, control); IL-1β (n = 4, control; n = 7, CUD); CX3CL1 (n = 1, CUD)
Abbreviations: ANCOVA = analysis of covariance; AUD = alcohol use disorders; CUD = cocaine use disorders; df = degree of freedom; Non-MDD = non-major
depressive disorders
https://doi.org/10.1371/journal.pone.0213791.t002
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alcohol groups (AUD/non-MDD and AUD/MDD patients) controlling for sex, age, BMI, and
antidepressant medication. Plasma concentrations and statistical analysis of inflammatory
mediators according to MDD in the cocaine and alcohol groups are described in Table 3.
One-way ANCOVA showed a main effect of MDD on the plasma concentrations of IL-1β
(p<0.05), CXCL12 (p<0.05), CCL11 (p<0.05), and CX3CL1 (p<0.05) in the cocaine group,
but no significant effects on any of these inflammatory mediators in the alcohol one. CUD/
MDD patients showed significantly lower IL-1β and CXCL12 concentrations than CUD/non-
MDD patients, and significantly higher CCL11 and CX3CL1 concentrations than CUD/non-
MDD patients.
Inflammatory mediators in relation to primary and substance-induced
major depressive disorders
SUD patients who were diagnosed with MDD were divided into primary and substance-
induced MDD according to DSM-IV-TR criteria. We investigated the impact of the type of
comorbid MDD in CUD and AUD patients using one-way ANCOVA for the cocaine (CUD/
non-MDD, CUD/primary MDD, and CUD/cocaine-induced MDD patients) and alcohol
groups (AUD/non-MDD, AUD/primary MDD, and AUD/cocaine-induced MDD patients),
controlling for sex, age, BMI, and antidepressant medication. Plasma concentrations and sta-
tistical analysis of inflammatory mediators according to type of MDD in the cocaine and alco-
hol groups are described in Table 4.
In a similar manner to previous results with comorbid MDD diagnosis, one-way ANCOVA
revealed a main effect of the type of MDD on the plasma concentrations of CXCL12 (p<0.05)
and CCL11 (p<0.01) in the cocaine group, but not in the alcohol one. The multiple compari-
sons test showed that CXCL12 concentrations were significantly lower in CUD/cocaine-
induced MDD patients than in CUD/non-MDD patients (p<0.05). The post hoc test also
revealed that CCL11 concentrations were significantly higher in CUD/primary MDD patients
than in CUD/non-MDD (p<0.01) and CUD/cocaine-induced MDD (p<0.01) patients.
Inflammatory mediators in cocaine use disorders as potential biomarkers
of comorbid major depressive disorders
Logistic regression models were generated to evaluate whether these cytokine and chemokine
concentrations could serve as explanatory variables in order to discriminate between primary
Table 3. Plasma concentrations of inflammatory mediators in the cocaine and alcohol groups according to comorbid depression.
VARIABLE COCAINE GROUP (CUD) (n = 64) ANCOVA (Statistics) (1) ALCOHOL GROUP (AUD) (n = 65) ANCOVA (Statistics) (1)
Non-MDD (n = 31) MDD (n = 33) F-value df p-value Non-MDD (n = 27) MDD (n = 38) F-value df p-value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
TNF-α (pg/mL) 8.00±5.11 9.80±5.58 0.992 1,57 0.319 10.27±5.97 9.67±5.03 0.077 1,59 0.782
IL-1β (pg/mL) 1.346±0.868 0.699±0.327 4.211 1,46 0.046 1.764±1.129 1.646±1.137 0.105 1,59 0.747
CXCL12 (pg/mL) 287.9±60.34 252.5±41.04 5.222 1,58 0.026 240.1±77.69 241.8±110.3 0.053 1,59 0.819
CCL2 (pg/mL) 38.70±9.303 43.36±12.89 0.853 1,58 0.360 39.01±16.28 34.89±16.14 1.568 1,59 0.215
CCL11 (pg/mL) 126.5±54.00 171.10±98.14 4.778 1,58 0.033 128.8±37.10 111.9±35.3 2.899 1,59 0.094
CX3CL1 (pg/mL) 1.987±1.666 2.342±1.252 5.807 1,55 0.019 1.839±1.090 2.212±1.298 1.742 1,59 0.192
(1) Statistical analysis was conducted on the logarithmic transformed values to ensure statistical assumptions. Data were analyzed by ANCOVA controlling for age, sex,
BMI, and antidepressant medication
Missing participants: TNF-α (n = 1, CUD/MDD); IL-1β (n = 7, CUD/non-MDD; n = 5, CUD/MDD); CX3CL1 (n = 1, CUD/non-MDD; n = 2, CUD/MDD)
Abbreviations: ANCOVA = analysis of covariance; AUD = alcohol use disorders; CUD = cocaine use disorders; df = degree of freedom; MDD = major depressive
disorder
https://doi.org/10.1371/journal.pone.0213791.t003
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MDD and substance induced-MDD in the cocaine group. The regression analyses included
additional variables (age, sex, and BMI) using different approaches and the resulting models
are represented in Table 5.
The full model included plasma concentrations of TNF-α, IL-1β, CXCL12, CCL2, CCL11, and
CX3CL1, and age, sex and BMI as independent variables in the logistic regression analysis in the
cocaine group. As depicted in Fig 1A, the ROC curve analysis showed an AUC = 0.914 (p<0.001),
which indicates a high discriminative power. A representative cut-off value was 0.452 [sensitivity
88.24 (95%CI = 63.56–98.54) and specificity 81.82 (95% CI = 48.22–97.72)]. Regarding the scatter
plot of the predictive probabilities for the type of MDD, their means were significantly different
between primary MDD and cocaine-induced MDD patients (U = 16.00, p<0.001).
To identify the most discriminative variables, a backward stepwise approach was used to
generate a logistic regression model in the cocaine group. This model was restricted to 3
explanatory variables in the equation: CXCL12 and CCL11 concentrations and sex. As
depicted in Fig 1B, the ROC analysis showed an AUC = 0.867 (p<0.001), maintaining a high
discriminative power. A representative cut-off value was 0.311 [sensitivity 77.78 (95%
CI = 52.36–93.59) and specificity 93.33 (95% CI = 68.05–99.83)]. The predictive probabilities
for the type of MDD also differed between primary MDD and cocaine-induced MDD patients
(U = 36.00, p<0.001).
Discussion
The main findings of this observational study are as follows: (a) There were differences in the
plasma concentrations of some inflammatory mediators between CUD (TNF-α, IL-1β and
Table 4. Plasma concentrations of inflammatory mediators in the cocaine and alcohol groups according to the type of depression.
VARIABLE COCAINE GROUP (CUD) (n = 64) ANCOVA
(Statistics) (1)






















Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
TNF-α (pg/
mL)
8.00±5.11 11.63±6.38 7.45±3.25 0.751 2,56 0.477 10.27±5.97 9.62±5.17 9.70±5.05 0.102 2,58 0.875
IL-1β (pg/
mL)
1.346±0.868 0.660±0.389 0.760±0.202 2.411 2,45 0.101 1.764±1.129 1.343±0.692 1.867±1.347 0.217 2,58 0.806
CXCL12 (pg/
mL)
287.9±60.34 265.5±42.56 236.9±34.26 a 4.453 2,57 0.016 240.1±77.69 248.7±66.69 236.8±134.8 0.415 2,58 0.662
CCL2 (pg/
mL)
38.70±9.303 45.40±14.15 40.91±11.16 0.501 2,57 0.609 39.01±16.28 30.96±13.71 37.74±17.45 1.444 2,58 0.244
CCL11 (pg/
mL)
126.5±54.00 211.7±111.4 aa 124.3±49.9 bb 6.445 2,57 0.003 128.8±37.10 115.4±39.4 109.3±32.8 1.401 2,58 0.255
CX3CL1 (pg/
mL)
1.987±1.666 2.272±1.195 2.439±1.371 0.134 2,54 0.875 1.839±1.090 2.116±1.387 2.283±1.259 0.864 2,58 0.427
(1) Statistical analysis was conducted on the logarithmic transformed values to ensure statistical assumptions. Data were analyzed by ANCOVA controlling for age, sex,
BMI, and antidepressant medication.
(a) p<0.05 and
(aa) p<0.01 denote significant differences versus cocaine non-MDD group after post hoc comparisons
(bb) p<0.01 denotes significant differences versus CUD primary MDD group after post hoc comparisons
Missing participants: TNF-α (n = 1, CUD/cocaine-induced MDD); IL-1β (n = 7, CUD/non-MDD; n = 1, CUD/primary MDD; n = 4, CUD/cocaine-induced MDD);
CX3CL1 (n = 1, CUD/non-MDD; n = 2, CUD/cocaine-induced MDD)
Abbreviations: ANCOVA = analysis of covariance; AUD = alcohol use disorders; CUD = cocaine use disorders; df = degree of freedom; MDD = major depressive
disorders
https://doi.org/10.1371/journal.pone.0213791.t004
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CCL11) and AUD (IL-1β and CXCL12) patients when compared with control subjects; (b)
CUD patients diagnosed with comorbid MDD showed significant differences in plasma con-
centrations of IL-1β, CXCL12, CCL11 and CX3CL1. In contrast, there were no differences in
the alcohol group; (c) Plasma CCL11 concentrations were found to be higher in CUD patients
with primary MDD than those with cocaine-induced MDD.
Evidence has revealed that the immune system participates in the mechanisms involved in
long-term adaptation and neurotoxicity associated with the substance use [35]. As conse-
quence of microglia activation, blood-brain-barrier disruption and neuroinflammation, proin-
flammatory mediators such as cytokines and chemokines are altered in the brain [36–37].
However, these changes are not restricted to the Central Nervous System, and alterations in
these inflammatory signals have been also found in the blood of SUD patients and proposed as
biomarkers of such disorders [38]. Thus, our results revealed that abstinent CUD patients had
lower concentrations of TNF-α and CCL11, and higher concentrations of IL-1β relative to
controls. Accordingly, a previous study in abstinent patients with a pathological use of cocaine
reported lower concentrations of TNF-α than controls and elevated concentrations of IL-1β in
those patients with a high number of DMS-IV-TR criteria for CUD [11]. These peripheral
alterations of relevant cytokines and CCL11 in the plasma of cocaine users could be associated
with changes in the expression of immune blood cells. In fact, acute cocaine administration in
rats produces increased levels of neutrophils and decreased levels of leukocytes and lympho-
cytes [39]. Interestingly, a study with cocaine-dependent volunteers reported a decrease in the
capacity of monocytes to express TNF-α and IL-6 compared with controls [40]. Unlike the
archetypal proinflammatory cytokines TNF-α and IL-1β, there is no literature linking cocaine
exposure with changes in plasma levels of CCL11. In contrast, a cross-sectional study has sug-
gested that current cannabis use is linked to increased plasma levels of CCL11 [41]. Regarding
AUD patients, significant alterations in the plasma were observed for IL-1β and CXCL12. Sim-
ilar to CUD patients, high concentrations of IL-1β were found in AUD patients, which has
been associated with an altered pattern of production of inflammatory cytokines in peripheral
blood monocytes from chronic alcohol patients [42]. In addition to IL-1β, a specific decrease
Table 5. Binary logistic regression models for predicting cocaine-induced depression through plasma concentrations of inflammatory mediators, sex, age, and
BMI.
MODEL VARIABLE B SEM W df p value Exp(B) 95% CI for Exp(B)
Lower Upper
LOGISTIC REGRESSION FULL MODEL 1
Method: Enter
TNF-α -0.204 0.144 2.005 1 0.157 0.816 0.616 1.081
IL-1β 2.809 2.493 1.270 1 0.260 16.597 0.125 2198
CXCL12 -0.021 0.017 1.401 1 0.237 0.980 0.947 1.014
CCL2 0.070 0.073 0.921 1 0.337 1.073 0.930 1.238
CCL11 -0.017 0.012 1.890 1 0.169 0.983 0.959 1.007
CX3CL1 0.308 0.602 0.262 1 0.609 1.361 0.418 4.426
Age -0.019 0.106 0.033 1 0.856 0.981 0.797 1.208
Sex 2.788 1.503 3.443 1 0.064 16.25 0.855 308.8
BMI -0.084 0.170 0.243 1 0.622 0.920 0.659 1.283
Constant 5.369 5.991 0.803 1 0.370 214.7 - -
LOGISTIC REGRESSION MODEL 2
Method: Backward Stepwise
CXCL12 -0.022 0.013 2.829 1 0.093 0.978 0.954 1.004
CCL11 -0.015 0.007 4.567 1 0.033 0.985 0.971 0.999
Sex 2.037 0.976 4.354 1 0.037 7.669 1.132 51.973
Constant 6.610 3.506 3.555 1 0.059 742.329
Abbreviations: B = coefficient; SEM = standard error; W = Wald test; df = degrees of Freedom; CI = confidence interval
https://doi.org/10.1371/journal.pone.0213791.t005
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in CXCL12 concentrations in AUD patients was found, which is in agreement with a previous
study from our group examining plasma chemokines in abstinent AUD patients in treatment
[30].
Among mood disorders, MDD is the comorbid psychiatric disorder more prevalent in
SUD patients [7]. Because cytokines play a role in neuronal integrity, neurogenesis and synap-
tic remodeling, growing evidence suggests that inflammatory mediators are involved in the
development of MDD [43]. Moreover, numerous studies have reported changes in circulating
proinflammatory cytokines in patients with MDD [44]. In the present study, we explored
Fig 1. ROC analysis and scatter dots for two logistic models to distinguish primary MDD from cocaine-induced MDD in the
cocaine group. (A) ROC analysis of a full model: TNF-α, IL-1β, CXCL12, CCL2, CCL11 CX3CL1, sex, age and BMI; and a scatter plot for
the predictive probabilities. (B) ROC analysis of an adjusted model: CXCL12, CCL11 and sex; and a scatter plot for the predictive
probabilities. Lines on the scatter plots are means and SD.
https://doi.org/10.1371/journal.pone.0213791.g001
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circulating cytokines and chemokines in SUD patients diagnosed with MDD. Notably, while
the diagnosis of comorbid MDD was associated with alterations in plasma concentrations of
some cytokines and chemokines in the CUD group, no differences were found in the AUD
group. Thus, CUD patients with comorbid MDD showed lower concentrations of IL-1β and
CXCL12, and higher concentrations of CX3CL1 and CCL11 as compared with than those
CUD patients without this condition. These results suggest that the type of SUD could have a
prominent effect on the detection of alterations in inflammatory mediators associated with
comorbid MDD. In addition to the type of substance, differences in other clinical and sociode-
mographic variables between both groups could be affecting the expression of circulating
inflammatory mediators, for example age and sex. Previously, we reported that plasma concen-
trations of IL-1β, CXCL12 and CX3CL1 are positively associated with the number of
DSM-IV-TR criteria for cocaine abuse and dependence. However, although cocaine users with
severe CUD displayed an elevated prevalence of mood disorders, no differences in the plasma
concentrations of these inflammatory mediators were reported [11]. In contrast, another
recent study in the same cohort with CUD patients reported no changes of CCL11 concentra-
tions relative to addiction-related variables or diagnosis of psychiatric comorbidity [13]. It is
important to point out that in both studies we explored the association of these inflammatory
mediators with psychiatric comorbidity at a level more general (mood disorders [11] or psy-
chiatric DSM-IV-TR Axis I disorders and personality disorders [13]). While we observed
lower plasma concentrations of IL-1β and CXCL12 in CUD patients with comorbid MDD,
other studies conducted in psychiatric patients with no interference of substances have showed
opposite results. For example, while increased IL-1β concentrations have been reported in
depressed individuals compared with controls [45], another clinical study showed increased
plasma levels of CXCL12 in MDD patients with different severities of depressive conditions
compared with a control group [46]. These data suggest that the co-occurrence of CUD and
MDD could prevent increased plasma concentrations of IL-1β and/or CXCL12 concentrations
when CUD or MDD are not comorbid. Unlike IL-1β and CXCL12, chemokines CX3CL1 and
CCL11 were found increased in CUD patients with MDD. Accordingly, transient elevated
serum levels of CX3CL1 have been described in colorectal cancer patients with anxiety and
depression [47]. Regarding CCL11, considerable evidence exists on the role of this chemokine
in the progression of neurodegenerative diseases (e.g., schizophrenia or dementia patients)
[22, 48], but contradictory results have been reported in relation to MDD. Thus, while changes
in CCL11 are observed in women with recurrent MDD with suicidal ideation [24] and in
young adults with mood disorders [49], another study in elderly patients with MDD showed
no changes [50].
Because there was a strong association between alterations in the plasma expression of cer-
tain inflammatory mediators and comorbid MDD, we extended our study in CUD patients
diagnosed with primary and cocaine-induced MDD. In fact, the differentiation between pri-
mary and substance-induced MDD in dual pathology is a field of study to be explored, and a
recent research has showed that platelet IRAS/nischarim (I1-Imidazoline receptor) could dis-
criminate between primary MDD and cocaine-induced MDD in CUD patients [51]. In our
study, we have observed differences in the plasma expression of CCL11 and CXCL12 accord-
ing to the type of MDD. Thus, CCL11 was increased in CUD patients with primary MDD rela-
tive to those with cocaine-induced MDD and non-comorbid patients. In the case of CXCL12,
CUD patients with cocaine-induced MDD showed decreased CXCL12 concentrations relative
to those with primary MDD and non-comorbid patients. Then, the ROC analysis of regression
models confirmed that CXCL12 and CCL11, in combination with sex, had a strong discrimi-
native power to discriminate between both types of MDD.
Inflammatory mediators as biomarkers for dual depression
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Limitations and strengths
Although our findings support the clinical importance of a differential diagnosis for MDD in
CUD and AUD, we are aware of important limitations. First, there is a growing number of
additional social, environmental and addiction-related variables (covariates) that could influ-
ence our data. Second, because the participants were under current treatment for SUD at the
moment of evaluation, we cannot exclude an influence of other psychiatric medications (e.g.,
anxiolytics and antipsychotics) on these inflammatory signals. Third, the impact of sex/gender
in the expression of inflammatory mediators is critical and, therefore, it is required a larger
sample size and a better characterization including other variables (e.g., sex hormones).
Fourth, a cross-validation of the proposed discriminative models is necessary to ensure reli-
ability and stability of the estimations. Fifth, the inclusion of patients diagnosed with MDD
and no history of SUD and healthy controls are needed for future research, even though these
psychiatric individuals have been previously described in the literature [45].
The strengths of the study are that we measured inflammatory mediators in a well-pheno-
typed cohort of subjects characterized by a marked presence of comorbid depressive disorders.
Furthermore, we employed a diagnostic procedure with good test-retest reliability, validity,
and inner rater reliability in the differentiation between primary and substance-induced MDD
[32].
Conclusions
Patients with dual depression have worse clinical evolution and worse therapeutic response.
Namely, the efficacy of antidepressant medication and/or psychological therapies in patients
with AUD or CUD and comorbid MDD can be influenced by the type of depression (i.e. pri-
mary and substance-induced MDD) (DSM-IV-TR). However, there are no biological sub-
strates that can reveal the difference between both mental conditions for a better clinical
management of these patients. The present study represents an attempt at the identification of
inflammatory biomarkers for the differentiation between primary and substance-induced dis-
orders. Although our findings indicate that plasma concentrations of chemokine CCL11 could
act as a potential biological marker to differentiate between primary and substance-induced
MDD in CUD patients, further clinical research is necessary to confirm the role of inflamma-
tory mediators in dual depression.
Supporting information
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(pg/mL) of TNF-, IL-, CXCL12, CCL2, CCL11 and CX3CL1.
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